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Summary: A method for the determination of inorganic sulphate based on high performance ion chromatography
is presented. The separation was performed on an anion-exchange column with a 1.8mmol/l sodium carbonate/
1.7 mmol/1 sodium hydrogen carbonate-buffer, pH 10.35. Conductivity of the eluate was monitored after suppression
of the background conductivity caused by the eluent-buffer.
Serum and synovial fluid samples were prepared by ultrafiltration through membranes with a molecular mass cut-
off of MT10000. The viscosity of the synovial fluids was reduced by treatment with hyaluronate lyase before
ultrafiltration.
The method showed a linear response for sulphate concentrations between 0.5 and 1000 μπιοΐ/ΐ. The limit of
detection was 1 umol/l for aqueous standards. For serum the coefficient of variation within-run was 2.3%—2.4%,
the coefficient of variation between days 2.9%-3.1%. For synovial fluids the coefficient of variation within-run
was 3.1%—3.4%, the coefficient of variation between days 4.6%—5.7%. Standard recovery experiments performed
by spiking pools of human sera containing low sulphate concentrations with sulphate concentrations between
5 μιηοΐ/ΐ and 40 μηιοΐ/ΐ showed recoveries between 98.9% and 100.6%. The corresponding experiments with pools
of synovial fluids showed recoveries of 98.3% to 100.9%.
As determined from 127 serum samples the reference range for sulphate was 262 μηιοΐ/ΐ—420 μπιοΐ/l, with a mean
value of 314 μηιοΐ/ΐ. No dependence on age or sex was observed.
The sulphate concentration in 36 synovial fluids from knees affected by inflammatory processes showed a
mean value of 424 μπιοΐ/l and a standard deviation of 70 μπιοΐ/ΐ. In 41 synovial fluids from knees affected by
chronic degenerative joint disease, the sulphate concentrations were statistically significantly lower, with a
mean of 374 μπιοΙ/1 and a standard deviation of 58 μηιοΐ/ΐ. The concentrations of sulphate in the synovial
fluids were statistically significantly higher than those in the serum samples used for determination of the
reference range.
Following the oral application of a subtoxic single dose of acetaminophen (32.5 mg/kg body weight—62.5 mg/kg
body weight) to 4 healthy volunteers, there was a significant decrease in the concentration of sulphate in serum
with a minimum at 4—5 h after application of the drug. The cumulative concentration decrease of sulphate in serum
and the kinetic constant of the sulphate depletion were not correlated with the applied acetaminophen dose normal-
ized for body weight.
Introduction
The main biological function of inorganic sulphate is to hydrolysis of the intermediate metabolite, pyrophos-
serve as a conjugation partner by forming sulphate esters phate, to orthophosphate.
with hydroxyl groups of endogeneous or exogeneous The conjugation process depends on a sulphotransferase,
metabolites. Adenosine triphosphate reacts with inor- which catalyses the transfer of a sulphate group to the
ganic sulphate to form adenosine-S'-phosphosulphate alcoholic or phenolic hydroxyl groups of the metabolite
and pyrophosphate; in a second reaction a phosphate from 3'-phosphoadenosine-5'-phosphate. Bile acids, ste-
group is transferred from a second adenosine triphos- roids and catecholamines (1) are subject to this type of
phate to adenosine-S'-phosphosulphate to give the conjugation, but sulphatation is also a vital step in the
"active sulphate", 3'-phosphoadenosine-5'-phosphosul- biosynthesis of proteoglycans and metabolites like
phate, as well as adenosine diphosphate. The reaction sulphocerebrosides. Sulphoconjugation also occurs in
is thermodynamically partially driven by the enzymatic the detoxification of serveral drugs, for example salicyl-
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amide, α-methyldopa and acetaminophen, which contain
alcoholic or phenolic hydroxyl groups.
In synovial fluid the concentration of inorganic anions is
regulated by Donnan equilibrium, and the concentrations
of anions like chloride and phosphate have been found to
be higher than in serum. More recent studies (2—4) have
shown that drugs used in the therapy of primary chronic
polyarthritis decrease the sulphate content of the glyco-
saminoglycans synthesized in cartilage.
In the present study a high performance ion chromato-
graphy (HPIC) method for the determination of sulphate
is reported. This was applied to the analysis of serum
and synovial fluid. An ultrafiltration procedure suitable
for the biological materials studied was used for the re-
quired deproteinization (5—6), and the effects of this
sample preparation on the analytical results were mini-
mized. A reference range for the concentration of sul-
phate in serum was established by analysing sera from
127 individuals. The concentrations of sulphate in syno-
vial fluids from patients with chronic degenerative joint
disease (n = 41) were compared with those in synovial
fluids from patients with inflammatory joint disease
(n = 36). Finally, the method was applied to kinetic
studies on the metabolism of subtoxic dosis of acetamin-
ophen in 4 healthy volunteers.
Materials and Methods
Chemicals
Potassium sulphate, 950 g/kg sulphuric acid, sodium carbonate, so-
dium hydrogen carbonate and 250 g/kg hydrochloric acid in at least
p. a. quality were from Merck (Darmstadt, Germany). Isotonic so-
dium chloride solution (154 mmol/1) was from dilutee Salvia
(Homburg/Saar, Germany). Hyaluronate lyase isolated from Strep-
tomyces hyalurolyticus was obtained from Behringwerke AG (Lie-
derbach, Taunus). The deionized water was prepared with a Milli-
Q-apparatus (Millipore GmbH, Eschborn, Germany).
The acetaminophen used for the kinetic studies was orally adminis-
tered to 4 healthy volunteers as ben-u-ron® 500 mg tablets in one
dose (33-62.5 mg/kg weight).
For determination of acetaminophen in serum a fluorescence polar-
isation immunoassay was used. The appropriate reagent kits and
controls for the TDX-FLX®-system were obtained from Abbott
GmbH (Wiesbaden-Delkenheim, Germany).
All blood specimens were collected in Sarstedt serum monovettes
containing separation gel. The reference range was determined
from serum samples drawn after 12 h fasting, when the basic clin-
ical chemistry (Na, K, C1, Ca, inorganic phosphate, total protein,
total cholesterol, triacylglycerols, glucose, uric acid, urea, creati-
nine, total bilirubin, aspartate aminotransferase, alanine amino-
transferase, γ-glutamyltransferase, alkaline phosphatase and total
creatine kinase) did not show any pathological abnormalities.
The synovial fluids used in this study were obtained from diagnos-
tic or therapeutic punctions of the knee joint of patients with in-
flammatory and chronic joint affections.
Instruments, settings and procedures
Ultrafiltration
The ultrafiltration was performed on an Amicon MPS-1 system
with YMT 30 100PK 14 mm membranes (Amicon, Witten, Ger-
many).
High performance ion chromatography
The Chromatographie analysis was performed on a HPLC-system
consisting of an ion Chromatograph DX-100 (DIONEX GmbH,
Idstein, Germany), containing an isocratic HPLC-pump and a con-
ductivity detector, connected to an autosampler WISP 71 OB
(Waters GmbH, Eschborn, Germany) and a Maxima 820 chroma-
tography manager with a two channel system-interface-module
(Waters GmbH, Eschborn, Germany) for system control, data
acquisition and peak integration. The complete fluidic of the auto-
sampler was passivated by 30% nitric acid before use.
For separation, an Ιοη-Pac AS4A (250 mm X 4 mm, DIONEX
GmbH, Idstein, Germany), combined with a AG4A (40 mm
X 4 mm, DIONEX GmbH, Idstein, Germany) was used. The eluent
contained 1.7 mmol/1 Na2CO3 and 1.8 mmol/1 NaHCO3 in deion-
ized water, pH 10.35; the flow rate was set to 2.0 ml/min; the
pressure in the Chromatographie system did not exceed 140 bar.
The retention times in this system were 1.2 min for fluoride, 2.3
min for chloride, 5.4 for phosphate and 6.2 min for sulphate.
The eluent of the column was passed through an anionic micro-
membrane suppressor AMMS-II (DIONEX GmgH, Idstein, Ger-
many) integrated in the DIONEX DX-100 instrument for the elimi-
nation of the background conductivity caused by the carbonate
buffer system. This ion exchanger was regenerated continuously
by 50 mmol/1 sulphuric acid. The conductivity was measured at a
sensitivity range of 10 μ8 full scale. The system was calibrated for
sulphate concentrations between 10 μιηοΐ/ΐ and 100 μηιοΐ/ΐ sulphate
with 4 standard solutions (10—25-50-100 μηιο1/1) prepared from
a stock standard containing 1 mmol/1 sodium sulphate by volumet-
ric dilution.
Analysis of the serum samples
Serum (150 μΐ) was diluted with deionized water to give a final
volume of 1500 μΐ. Of this diluted serum 500 μΐ were filtered
through the MPS-1-ultrafiltration device by centrifugation at
2000 g and 4 °C for 25 min; the resulting 400 μΐ ultrafiltrate were
discarded. Then 900 μΐ diluted serum were filtered through the
same membrane under the same conditions. Of this ultrafiltrate
50 μΐ were injected by the autosampler for analysis by ion chroma-
tography.
Analysis of the synovial fluid samples
Hyaluronate lyase (150 mg, 300—400 Units/mg) was dissolved in
100 ml isotonic sodium chloride (154 mmol/1). Ten (10) μΐ of this
solution were added to 300 μΐ synovial fluid and the mixture incu-
bated for 30 min at 37 °C. After degradation of the hyaluronate the
viscosity of the synovial fluid was comparable to that of serum.
Hundred and fifty (150) μΐ of this mixture were then treated as
described for serum samples.
Statistical calculations
All statistical calculations were done with the aid of the software
package Jandel Sigmastat Version 1 (Jandel Scientific GmbH,
Schimmelbuschstra e 25, D-40699 Erkrath, Germany). The Kol-
mogorov-Smirnov test with Lilliefors' correction was used to test
data for normality of the estimated underlying population. The two
sample t-test was used for the parametric comparison of two sam-
ples, which were drawn from normally distributed populations with
the same variances.
Results
Chromatography
Ultrafiltration proved to be a suitable method of sample
preparation for the determination of sulphate in serum
and in synovial fluid. Figure la shows the chromato-
gram of a sulphate standard, figure Ib that of a serum
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ultrafiltrate, figure Ic that of a synovial fluid ultrafil-
trate. Chloride and phosphate were well separated from
sulphate, and no other anion interfering with sulphate
was observed.
The signal of the conductivity detector was linear for
injected amounts of 500 pmol to 50 nmol, equivalent to
the concentration range 10 μηιο1/1-1000 μπιοΙ/1 (data
shown in figure 2).
Optimization of the ultrafiltration
The ultrafiltration membranes showed a significant
content of sulphate and a capacity for the unspecific ad-
sorption of sulphate. The recovery of an aqueous solu-
tion containing 0.625 umol/1 sulphate was 170—200%,
that of a solution containing 80 μηιοΐ/ΐ sulphate was
80—90%, regardless of whether the membranes were
previously conditioned with deionized water or not. This
effect could be minimized by a two-step ultrafiltration
procedure, discarding the ultrafiltrate of the first 500 μΐ
aliquot of the diluted serum/synovial fluid, and using the
second ultrafiltrate. Using this sample preparation we
studied the effect of serum protein on the fraction of
ultrafiltratable sulphate by standard recovery experi-
Retention time [min]
Fig. la—c Chromatogram of
(a) a sulphate standard containing 250 umol/1 sulphate,
(b) a serum sample containing 232 μηιοΐ/ΐ sulphate and
(c) a synovial fluid sample containing 307 umol/1 sulphate.
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Fig. 2 Linearity of the peak height in dependence on the amount
of sulphate injected into the ion-chromatograph.
ments. A serum pool (sulphate concentration: 350
umol/l) was prepared, then 150 μΐ serum pool, 150 μΐ
of a sulphate standard and 1200 μΐ deionized water were
mixed, and this dilution was ultrafiltered. Synovial flu-
ids were pretreated with hyaluronate lyase, pooled and
then processed like the pooled sera. Table 1 summarizes
the results of these experiments, which showed a 100%-
recovery for the range 5 μηιοΐ/ΐ to 40 μιηοΐ/ΐ sulphate
added to both the 1 : 10 dilutions of the pooled sera and
the 1 : 10 dilutions of the pooled synovial fluids.
Imprecision
The within-run imprecision (tab. 2a) was below 1.5%
for standards, below 2.5% for the pooled sera and below
3.5% for the pooled synovial fluids. The between-run
imprecision (tab. 2b) was about 3% for the pooled sera
and below 6% for the pooled synovial fluids. The theo-
retical limit of detection was 1.05 μηιοΐ/l, determined by
the method described by Long & Winefolder (7), con-
sidering the standard deviations of the quantities de-
scribing the calibration line, as well as the mean and
Tab. 1 Recovery of sulphate standard added to a 1 : 10 diluted
pool of human sera (sulphate concentration 375 umol/l) and to a
1:10 diluted pool of synovial fluids (sulphate concentration 290
μιηοΐ/ΐ), ultrafiltered after standard addition (n = 10 determin-
ations)
Sulphate concentration
[umol/l] added to
1 : 10 dilution of pooled
sera/synovial fluids
5
15
25
40
Recovery [%]
in serum
99.4 ± 4.2
100.6 ± 3.9
98.9 ± 2.0
98.9 ± 2.3
Recovery [%]
in synovial fluid
100.9 ± 0.6
98.5 ± 2.3
98.9 ± 1.4
98.3 ± 2.9
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Tab. 2a Within-run imprecision for the determination of sul-
phate, calculated for four standards, two pooled human sera and
two pooled synovial fluids, calculated from n = 10 runs of the
1:10 dilutions of the standards or the ultrafiltrates of 1
tions of the sera and synovial fluids.
10 dilu-
Sulphate [umol/1]
Target
Mean
SD
CV in %
Standard
1
50
49.2
0.8
1.6
Standard
2
100
101.5
1.4
1.4
Standard
3
200
202.3
2.8
1.4
Standard
4
400
397.5
4.8
1.2
Pooled
serum 1
289.2
6.9
2.4
Pooled
serum 2
376.4
8.7
2.3
Pooled
synovial
fluid 1
311.3
10.6
3.4
Pooled
synovial
fluid 2
406.2
12.6
3.1
Target = the concentration assigned to the standards, which were
also used for calibration of the method.
SD = Standard deviation
CV = Coefficient of variation in %
Tab. 2b Between-run imprecision for the determination of sul-
phate, calculated for two pooled human sera and two pooled syno-
vial fluids, calculated from n = 10 runs of the ultrafiltrates of
1 : 10 dilutions of the sera and synovial fluids.
Sulphate [umol/1]
Mean
SD
CV in %
Pooled
serum
1
285.3
8.8
3.1
Pooled
serum
2
384.3
11.1
2.9
Pooled
synovial
fluid 1
316.4
18.0
5.7
Pooled
synovial
fluid 2
414.3
19.1
4.6
SD = Standard deviation
CV = Coefficient of variation in %
the standard deviation of the peak-to-peak noise of the
baseline signal.
Reference range in serum
The reference range for sulphate in serum was deter-
mined for serum samples from 69 male and 58 female
subjects. The observed reference range showed no de-
pendence on sex and age. For all 127 individuals the
mean sulphate concentration in serum was 314 μηιοΙ/1
with a standard-deviation of 36 μηιοΙ/1, ranging from
262 μηιοΐ/l to 420 μηιοΙ/1. The data did not match the
pattern expected for data drawn from a normal distrib-
uted population (Komolgorov-Smirnov-test, K-S dis-
tance = 0.1151, Ρ = 0.0007).
Sulphate concentration in pathological
synovial fluids
Figure 3 shows the distribution of the concentrations
found for sulphate in pathological synovial fluids. For
36 synovial fluids from knees affected by inflamma-
tory processes we obtained a range (mean ± standard
deviation) of 424 μηιοΙ/1 ± 70.1 μηιοΐ/ΐ. For 41 syno-
vial fluid from knees affected by chronic degenerative
joint disease the range was (mean ± standard devia-
tion) 374 μηιοΐ/l ± 69.9 μηιοΙ/1. The values for both
groups were as expected for data drawn from a nor-
mally distributed population and showed an equal vari-
ance. Comparison of the two groups by a t-test re-
vealed a difference for the mean values greater than
would be expected by chance (t = 3.09 with 75 de-
grees of freedom, Ρ = 0.0028).
Kinetics of sulphate in serum following the
administration of acetaminophen
Figure 4 and table 3 summarize the data for the kinetic
studies of the concentrations of sulphate and acetamino-
phen in serum following oral administration of a single
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Fig. 3a—b Distribution of the sulphate concentrations measured
in synovial fluid of (a) inflammatory joint diseases and (b) chronic
degenerative joint diseases.
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Fig. 4a—d Time-course of the decrease of sulphate and acetaminophen after administration of
(a) acetaminophen 30 mg/kg body weight, (d) acetaminophen 33 mg/kg body weight.
(b) acetaminophen 62.5 mg/kg body weight, · = sulphate concentration
(c) acetaminophen 50 mg/kg body weight, · = acetaminophen concentration
dose of acetaminophen (33-62.5 mg/kg body weight)
to 4 healthy, previously fasting (for at least 12 hours)
volunteers.
The resorption and metabolism of acetaminophen could
be described as a first order kinetic process with a re-
sorption constant larger than the elimination constant.
The peak concentration of acetaminophen reached in se-
rum, calculated from the Bateman equation (8) used for
fitting the data, was correlated with the applied dose
normalized for body weight. The decay constant k3 was
0.35 ± 0.06 h"1 (mean ± standard deviation). The me-
tabolism of acetaminophen showed a decay constant of
0.35 ± 0.06 h"1 (mean ± standard deviation) for the
four volunteers. In all cases, the decay kinetics of the
sulphate in serum were also first order, but the variation
of the decay constant k was large. Neither the kinetic
constant nor the cumulative loss of sulphate in serum
(41% to 74% of the initial sulphate concentration) due
to the administration of acetaminophen were correlated
with the applied dose of acetaminophen.
Discussion
The objective of this study was the determination of in-
organic sulphate in serum and synovial fluid. Colorimet-
ric methods using benzidine (9), barium chloranilate
(10) or rhodizonate (11) as well as turbidimetric meth-
ods based on the detection of barium sulphate (12) have
been described for the determination of inorganic sul-
phate in biological materials. All these methods have
limited sensitivity and precision due to the required sam-
ple preparation procedures and the analytical principle;
the results are also strongly influenced by the matrix of
the sample analysed. Several slightly different methods
for the determination of sulphate in serum by high-per-
formance-ion-chromatography with conductivity detec-
tion have also been described (5, 13 — 16). The advant-
age of these methods is that deproteinization is the only
sample pretreatment required. Furthermore, the quantifi-
cation does not depend on the use of an internal stan-
dard. In the present study ultrafiltration was choosen for
deproteinization, since it is more effective than precipi-
Tab. 3 Kinetic studies on sulphate consumption due to acetaminophen administration.
The kinetic of sulphate consumption was approximated as c(t) = cx + (c0 — c«) · e"
The kinetic of acetaminophen was approximated as c(t)
Volunteer
(sex)
lo"
3?
4?
Acetaminophen
administered
(mg/kg
body weight)
30
62.5
50
33
«krkz-ie- 1^ •'-(e^'O/ika
Sulphate kinetics
Co
(umol/1)
321
287
315
401
Coo
(umol/1)
189
129
82
136
(%ofc0)
59
45
26
34
Decay
constant k
1.23
0.36
0.19
0.43
-k2).
Acetaminophen kinetics
(umol/1)
175
398
323
178
Time at
(hT
1.03
1.04
0.16
0.91
Decay
constant k3
0.43
0.31
0.29
0.37
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tation (16). No interference by a precipitation agent can
occur, and sample preparation is much more reproduc-
ible and allows better standardization. The only draw-
back is the unspecific binding of sulphate to the ultrafil-
tration membranes. Methods for elimination of sulphate
contamination of the ultrafiltration membranes have
been described previously (5—6), but the issue of unspe-
cific binding of the analyte from the samples to the
membranes, leading to a reduced recovery as well as
precision, was not addressed. The method described here
involves a sequence of two ultrafiltrations of diluted ali-
quots of a sample. The function of the first step was
to equilibrate the membranes with the sulphate of the
individual samples; the ultrafiltrate obtained was dis-
carded. Analysis of the ultrafiltrate of the second aliquot
showed an imprecision lower than 2%. The inaccuracy,
assessed by standard recovery experiments, was also
within these limits.
The reference range for sulphate in serum was studied
in samples from blood-donors and apparently healthy
volunteers and did not show any dependence on age and
sex. The mean concentration in serum was 314 μηιοΐ/l,
and a broad, non-normal distribution from 242 μπιοΐ/ΐ
to 385 μηιοΐ/ΐ was observed. This non-normal distribu-
tion may be due to inter-individual as well as intra-indi-
vidual fluctuations of the sulphate concentration in se-
rum arising from the present pool and recent intake of
sulphate-generating aminoacids as well as the renal sul-
phate elimination. Since all samples were drawn in the
morning from individuals who had fasted for at least 12
hours, effects due to recent nutritive ingestion of sul-
phate precursors and due to a circadian rhythm de-
scribed previously (17) should have been prevented.
Furthermore we studied the sulphate concentration in 36
synovial fluids from knees affected by inflammatory
processes and 41 synovial fluids from knees affected by
chronic degenerative joint disease.
Non-pathological synovial fluids from patients without
any joint disease were not available for ethical reasons,
so the study was limited to the comparison of the two
major groups defined by the criteria described pre-
viously (18-19). For the group of synovial fluids from
patients suffering from inflammatory joint disease the
sulphate concentrations found were significantly higher
(t-test) than those found for the group of synovial fluids
from patients suffering from chronic degenerative joint
disease. There may be several reasons for the differences
between the two groups. Due to the greater permeability
of the blood-synovia-barrier in the case of inflammatory
joint diseases, the higher sulphate concentration cannot
be described as analogous to the higher protein concen-
trations found in these cases, because the concentrations
of most constituents in synovial fluid approach the con-
centrations in serum with increasing permeability of the
blood-synovia-barrier (19). An association of the differ-
ences in the concentrations of sulphate in the synovial
fluid with the inflammatory activity of the joint process
seems more likely. In inflammatory joint disease the
metabolic activity in the synovial system and the degra-
dation of the joint cartilage with degradation of sul-
phated proteoglycans and glycosaminoglycans are ac-
celerated. Besides these processes there is an induction
of biosynthetic activity for the reconstruction of the
components of the synovial system mediated by cyto-
kines and growth factors (20). Activation of regulatory
processes enhancing the synthesis of new sulphated pro-
teoglycans may therefore also be responsible for the
higher concentration of sulphate in the synovial fluid in
cases of inflammatory joint disease.
In four volunteers we studied the changes of concentra-
tion of sulphate in serum due to an intake of acetamino-
phen. An exponential time-dependent decrease of the
concentration of sulphate in serum accompanying the
elimination of acetaminophen was observed. The decay
constant as well as the cumulative concentration
decrease of sulphate in serum were not correlated with
the dose of acetaminophen normalized for body weight,
or with the peak acetaminophen concentration in serum.
The role of sulphate in cellular metabolism as well as
the sulphate depletion in serum due to drug metabolism
have been described by other authors (21 —24). This sul-
phate trapping may be an intrinsic effect of antiinflam-
matory drugs (22—23). Chronic intake of drugs subject
to conjugation with sulphate may lead to a permanently
reduced sulphate concentration in serum. Sulphate trap-
ping by drugs in serum may consecutively lead to a re-
duced sulphate concentration in the synovial fluid. Sul-
phate is necessary for the biosynthesis of sulphated pro-
teoglycans, so that sulphate depletion in the synovial
fluid may have a negative impact on the quantity and
the composition of the proteoglycans synthesized (2—4).
These altered proteoglycans may enhance the destruc-
tion of the cartilage. Since several drugs used commonly
in pain therapy of arthritis have sulphate-depleting ef-
fects like acetaminophen (24), this sulphate trapping
may manifest itself as an adverse side-effect. The poten-
tial of such drugs for enhancing the progression of the
cartilage destruction has to be studied further in clin-
ical trials.
The determination of sulphate in serum may also be use-
ful for the follow-up of patients suffering from intoxica-
tion with acetaminophen. Since the pool of sulphate is
limited and may only be restored by metabolism of sul-
phur-containing amino acids, the course of the concen-
tration of sulphate in serum gives additional important
information in these circumstances. In animal experi-
ments, a permanently low sulphate concentration in se-
rum has been shown to result in non-linear kinetics and
decreased efficiency for the elimination of drugs (25).
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